253
Views
13
CrossRef citations to date
0
Altmetric
Original Research Report

A split-face study using Botulinum Toxin type B to decrease facial Erythema index

, , , , &
Pages 243-248 | Received 01 Jun 2011, Accepted 31 Jul 2011, Published online: 17 Aug 2011

References

  • Low DA, Hubing KA, Del Coso J, Crandall CG. Mechanisms of cutaneous vasodilation during the postmenopausal hot flash. Menopause. 2010.
  • Sterodimas A, Nicolaou M, Paes TR. Successful use of Botulinum toxin-A for the treatment of neck and anterior chest wall flushing. Clin Exp Dermatol. 2003;28:592–594.
  • Yuraitis M, Jacob CI. Botulinum toxin for the treatment of facial flushing. Dermatol Surg. 2004;30:102–104.
  • Pierard GE. EEMCO guidance for the assessment of skin colour. J Eur Acad Dermatol Venereol. 1998;10:1–11.
  • Dressler D, Hallett M. Immunological aspects of Botox, Dysport and Myobloc/NeuroBloc. Eur J Neurol. 2006;13(Suppl 1):11–15.
  • Dressler D, Benecke R. Pharmacology of therapeutic botulinum toxin preparations. Disabil Rehabil. 2007;29:1761–1768.
  • Aoki KR. Pharmacology and immunology of botulinum neurotoxins. Int Ophthalmol Clin. 2005;45:25–37.
  • Arat YO, Yen MT. Effect of botulinum toxin type a on tear production after treatment of lateral canthal rhytids. Ophthal Plast Reconstr Surg. 2007;23:22–24.
  • Fagien S, Cox SE, Finn JC, Werschler WP, Kowalski JW. Patient-reported outcomes with botulinum toxin type A treatment of glabellar rhytids: a double-blind, randomized, placebo-controlled study. Dermatol Surg. 2007;33:S2–S9.
  • Hui JI, Lee WW. Efficacy of fresh versus refrigerated botulinum toxin in the treatment of lateral periorbital rhytids. Ophthal Plast Reconstr Surg. 2007;23:433–438.
  • de Boulle K. Patient satisfaction with different botulinum toxin type A formulations in the treatment of moderate to severe upper facial rhytids. J Cosmet Laser Ther. 2008;10: 87–92.
  • Carruthers A, Carruthers J. A single-center, dose-comparison, pilot study of botulinum neurotoxin type A in female patients with upper facial rhytids: safety and efficacy. J Am Acad Dermatol. 2009;60:972–979.
  • Wollina U, Karamfilov T. Adjuvant botulinum toxin A in dyshidrotic hand eczema: a controlled prospective pilot study with left-right comparison. J Eur Acad Dermatol Venereol. 2002;16:40–42.
  • Klein AW. Treatment of dyshidrotic hand dermatitis with intradermal botulinum toxin. J Am Acad Dermatol. 2004;50:153–154; author reply 154.
  • Swartling C, Naver H, Lindberg M, Anveden I. Treatment of dyshidrotic hand dermatitis with intradermal botulinum toxin. J Am Acad Dermatol. 2002;47:667–671.
  • Frasson E, Brigo F, Acler M, Didone G, Vicentini S, . Botulinum toxin type A vs type B for axillary hyperhidrosis in a case series of patients observed for 6 months. Arch Dermatol. 2011;147:122–123.
  • Campanati A, Sandroni L, Gesuita R, Giuliano A, Giuliodori K, . Treatment of focal idiopathic hyperhidrosis with Botulinum Toxin Type A: clinical predictive factors of relapse-free survival. J Eur Acad Dermatol Venereol. 2010.
  • Bosdotter Enroth S, Rystedt A, Covaciu L, Hymnelius K, Rystedt E, . Bilateral forearm intravenous regional anesthesia with prilocaine for botulinum toxin treatment of palmar hyperhidrosis. J Am Acad Dermatol. 2010;63:466–474.
  • Gregoriou S, Rigopoulos D, Makris M, Liakou A, Agiosofitou E, . Effects of botulinum toxin-a therapy for palmar hyperhidrosis in plantar sweat production. Dermatol Surg. 2010;36:496–498.
  • Coutinho dos Santos LH, Gomes AM, Giraldi S, Abagge KT, Marinoni LP. Palmar hyperhidrosis: long-term follow-up of nine children and adolescents treated with botulinum toxin type A. Pediatr Dermatol. 2009;26:439–444.
  • Wang CC, Wang CP. Preliminary experience with botulinum toxin type A intracutaneous injection for Frey's syndrome. J Chin Med Assoc. 2005;68:463–467.
  • Ng S, Torjek C, Hovan A. Management of Frey syndrome using botulinum neurotoxin: a case report. J Can Dent Assoc. 2009;75:651–654.
  • Cantarella G, Berlusconi A, Mele V, Cogiamanian F, Barbieri S. Treatment of Frey's syndrome with botulinum toxin type B. Otolaryngol Head Neck Surg. 2010;143:214–218.
  • Tugnoli V, Marchese Ragona R, Eleopra R, Quatrale R, Capone JG, . The role of gustatory flushing in Frey's syndrome and its treatment with botulinum toxin type A. Clin Auton Res. 2002;12:174–178.
  • Kranendonk SK, Ferris LK, Obagi S. Re: Botulinum toxin for the treatment of facial flushing. Dermatol Surg. 2005;31:491; author reply 492.
  • Alexandroff AB, Sinclair SA, Langtry JA. Successful use of botulinum toxin a for the treatment of neck and anterior chest wall flushing. Dermatol Surg. 2006;32:1536.
  • Lagalla G, Millevolte M, Capecci M, Provinciali L, Ceravolo MG. Long-lasting benefits of botulinum toxin type B in Parkinson's disease-related drooling. J Neurol. 2009;256: 563–567.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.